Dr Michael Gilman, Obsidian

To get started in the New Year, we decided to roll out a new mini series on small cap and private biotechs, as seen through the lens of their dynamic CEOs.

This will run throughout January, with plenty of different products and perspectives to consider.

The honour for the very first CEO to be in the hot seat in 2018 went to Dr Nancy Simonian of Syros earlier this week during JPM18, who talks about their small molecule program and why they are excited about 2018.

When we first talked to Syros, they were a privately held start-up, now they’re listed on Nasdaq.

We now move on to the second one in the series, with a look at a new start-up called Obsidian Therapeutics in an interview with Dr Michael Gilman (right).

To learn more and get a heads up on our latest CEO interview, subscribers can log-in or you can click to gain access to BSB Premium Content.

Posted by